{"id":"terazosin-hytrin","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Dizziness"},{"rate":"5-10%","effect":"Headache"},{"rate":"5-10%","effect":"Fatigue"},{"rate":"5-10%","effect":"Orthostatic hypotension"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By blocking alpha-1 adrenergic receptors, terazosin decreases the muscle tone in the prostate and bladder neck, allowing for easier urination. This mechanism is specific to the treatment of benign prostatic hyperplasia and hypertension.","oneSentence":"Terazosin is an alpha-1 adrenergic receptor antagonist that relaxes smooth muscle in the prostate and bladder neck, improving urine flow and reducing symptoms of benign prostatic hyperplasia.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:54:02.036Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Benign prostatic hyperplasia"},{"name":"Hypertension"}]},"trialDetails":[{"nctId":"NCT07464028","phase":"PHASE2","title":"Terazosin And Metabolic Energetics in Parkinson's Disease","status":"NOT_YET_RECRUITING","sponsor":"Nandakumar Narayanan","startDate":"2026-07-01","conditions":"Parkinson's Disease (PD)","enrollment":120},{"nctId":"NCT04760860","phase":"PHASE1, PHASE2","title":"Terazosin for Dementia With Lewy Bodies","status":"NOT_YET_RECRUITING","sponsor":"Qiang Zhang","startDate":"2027-10","conditions":"Dementia With Lewy Bodies","enrollment":40},{"nctId":"NCT07224269","phase":"EARLY_PHASE1","title":"Effect of Terazosin on ATP Levels in People With Amyotrophic Lateral Sclerosis","status":"NOT_YET_RECRUITING","sponsor":"University of Iowa","startDate":"2026-05-01","conditions":"Amyotrophic Lateral Sclerosis, Adenosine Triphosphate Activities","enrollment":20},{"nctId":"NCT04386317","phase":"PHASE2","title":"Terazosin Effect on Cardiac Changes in Early Parkinson's Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Cedars-Sinai Medical Center","startDate":"2020-11-01","conditions":"REM Sleep Behavior Disorder, Pre-motor Parkinson's Disease, Symptomatic Parkinson Disease","enrollment":15},{"nctId":"NCT05109364","phase":"PHASE2","title":"Terazosin and Parkinson's Disease Extension Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Cedars-Sinai Medical Center","startDate":"2022-09-23","conditions":"Symptomatic Parkinson Disease, REM Sleep Behavior Disorder, Pre-motor Parkinson's Disease","enrollment":15},{"nctId":"NCT07288450","phase":"PHASE1, PHASE2","title":"Terazosin And Metabolic Engagement in Parkinson's Disease","status":"NOT_YET_RECRUITING","sponsor":"Nandakumar Narayanan","startDate":"2026-09-01","conditions":"Parkinson's Disease","enrollment":100},{"nctId":"NCT07207057","phase":"PHASE3","title":"Edmond J. Safra Accelerating Clinical Trials in Parkinson's Disease: A Multiarm Multi-stage Platform Trial","status":"RECRUITING","sponsor":"University College, London","startDate":"2025-09-12","conditions":"Parkinsons Disease (PD)","enrollment":1200},{"nctId":"NCT06966804","phase":"PHASE3","title":"Comparison of Alpha Blockers (Terazosin and Tamsulosin) in Reducing Ureteral Stent Related Symptoms","status":"RECRUITING","sponsor":"Penang Hospital, Malaysia","startDate":"2025-06-01","conditions":"Stent Related Symptoms","enrollment":150},{"nctId":"NCT06863558","phase":"PHASE3","title":"Reduction of Edema With a Specialized Cocktail for Ultra-early Management in Intracerebral Hemorrhage","status":"NOT_YET_RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2025-05-08","conditions":"Intracerebral Hemorrhage","enrollment":58},{"nctId":"NCT06863571","phase":"PHASE3","title":"Reduction of Edema With a Specialized Cocktail for Ultra-early Management in Ischemic Stroke","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2025-04-12","conditions":"Ischemic Stroke","enrollment":68},{"nctId":"NCT04551040","phase":"PHASE1","title":"Target Engagement of Terazosin in Healthy Adults","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Iowa","startDate":"2021-03-26","conditions":"Healthy","enrollment":18},{"nctId":"NCT03339258","phase":"PHASE2","title":"A Randomized Controlled Trial of Doxazosin for Nightmares, Sleep Disturbance, and Non-Nightmare Clinical Symptoms in PTSD","status":"ACTIVE_NOT_RECRUITING","sponsor":"San Francisco Veterans Affairs Medical Center","startDate":"2018-04-15","conditions":"Stress Disorders, Post-Traumatic","enrollment":80},{"nctId":"NCT05855577","phase":"PHASE4","title":"Motor Function Efficacy of Pharmacological Treatments Targeting Energy Metabolism, in Parkinson's Patients","status":"NOT_YET_RECRUITING","sponsor":"I.R.C.C.S. Fondazione Santa Lucia","startDate":"2023-12","conditions":"Parkinson Disease, Gait Analysis, Therapy, Directly Observed","enrollment":50},{"nctId":"NCT02046395","phase":"PHASE4","title":"Effect of Renin-angiotensin-system Blockade on Urinary Free Light Chains in Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Tulane University School of Medicine","startDate":"2012-01","conditions":"Type 2 Diabetes, Hypertension","enrollment":28},{"nctId":"NCT03905811","phase":"PHASE1, PHASE2","title":"A Pilot Study of Terazosin for Parkinson's Disease","status":"COMPLETED","sponsor":"Jordan Schultz","startDate":"2019-09-24","conditions":"Parkinson Disease","enrollment":13},{"nctId":"NCT04557072","phase":"","title":"Selective Versus Nonselective Alpha-blockade Prior to Pheochromocytoma Resection - Systematic Review and Meta-analysis","status":"COMPLETED","sponsor":"Jagiellonian University","startDate":"2020-08-01","conditions":"Pheochromocytoma","enrollment":1344},{"nctId":"NCT04467931","phase":"","title":"ACEI or ARB and COVID-19 Severity and Mortality in US Veterans","status":"COMPLETED","sponsor":"University of Utah","startDate":"2020-01-19","conditions":"Hypertension, COVID","enrollment":22213},{"nctId":"NCT04132583","phase":"PHASE1","title":"Deflox Tablets Bioequivalence (BE) Trial","status":"COMPLETED","sponsor":"Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany","startDate":"2019-09-21","conditions":"Healthy","enrollment":16},{"nctId":"NCT03195673","phase":"PHASE2","title":"Safety and Efficacy of Low Dosage of Terazosin in Subjects Undergoing Carotid Artery Stenting","status":"UNKNOWN","sponsor":"Capital Medical University","startDate":"2018-03-02","conditions":"Carotid Artery Stenosis","enrollment":160},{"nctId":"NCT03653845","phase":"PHASE3","title":"Adrenal Artery Ablation for Primary Aldosteronism","status":"UNKNOWN","sponsor":"Third Military Medical University","startDate":"2018-07-01","conditions":"Primary Aldosteronism, Hypertension","enrollment":40},{"nctId":"NCT01323998","phase":"","title":"Benign Prostatic Hypertrophy Treatment Patterns & Outcomes: Marketscan","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-04","conditions":"Prostatic Hyperplasia","enrollment":35032},{"nctId":"NCT01332435","phase":"","title":"Dutasteride in Enlarged Prostate Economic Assessment: A Retrospective Database Pooled Analysis of Early 5-alpha Reductase Inhibitor Use","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-11","conditions":"Prostatic Hyperplasia","enrollment":6896},{"nctId":"NCT00438113","phase":"PHASE4","title":"Atrial Substrate Modification With Aggressive Blood Pressure Lowering to Prevent AF","status":"COMPLETED","sponsor":"Nova Scotia Health Authority","startDate":"2009-12","conditions":"Atrial Fibrillation","enrollment":184},{"nctId":"NCT01332487","phase":"","title":"Evaluating the Impact of Early Versus Delayed 5 Alpha Reductase Inhibitor Treatment on the Risk of Emergent Surgery in Men With Benign Prostatic Hyperplasia","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-08","conditions":"Prostatic Hyperplasia","enrollment":4068},{"nctId":"NCT01386983","phase":"","title":"Clinical and Economic Outcomes of Patients Utilizing Combination Therapy for Enlarged Prostates: A Henry Ford Database Assessment","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-03","conditions":"Prostatic Hyperplasia","enrollment":332},{"nctId":"NCT01390870","phase":"","title":"Establishing Predictors of Enlarged Prostate Treatment Adherence: Linking Symptom Improvement to Adherence","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-05","conditions":"Prostatic Hyperplasia","enrollment":400},{"nctId":"NCT01435954","phase":"","title":"Clinical Progression and Costs in Benign Prostatic Hyperplasia Patients Treated With Early Versus Delayed Combination Therapy","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-08","conditions":"Benign Prostatic Hyperplasia","enrollment":13551},{"nctId":"NCT00000620","phase":"PHASE3","title":"Action to Control Cardiovascular Risk in Diabetes (ACCORD)","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"1999-09","conditions":"Atherosclerosis, Cardiovascular Diseases, Hypercholesterolemia","enrollment":10251},{"nctId":"NCT02966717","phase":"PHASE2","title":"Rituximab Combined With MSCs in the Treatment of PNS (3-4 Stage of CKD)","status":"UNKNOWN","sponsor":"Zhujiang Hospital","startDate":"2016-08","conditions":"Renal Insufficiency, Chronic, Nephrotic Syndrome","enrollment":116},{"nctId":"NCT00449683","phase":"PHASE4","title":"Excessive Sweating Caused by Antidepressants: Measurement and Treatment With Terazosin","status":"COMPLETED","sponsor":"Thomas Jefferson University","startDate":"2007-03","conditions":"Hyperhidrosis","enrollment":23},{"nctId":"NCT01508637","phase":"NA","title":"Diesel Exhaust and Vascular Function","status":"UNKNOWN","sponsor":"University of Washington","startDate":"2012-01","conditions":"Cardiovascular Effects","enrollment":24},{"nctId":"NCT01530243","phase":"PHASE2, PHASE3","title":"The Effect of Terazosin and Tolterodine on Ureteral Stent Related Symptoms","status":"COMPLETED","sponsor":"Urmia University of Medical Sciences","startDate":"2012-01","conditions":"Disorder of Urinary Stent","enrollment":104},{"nctId":"NCT01366664","phase":"PHASE1","title":"A Pharmacodynamic Study of Dapoxetine Concomitantly Administered in Participants Taking Terazosin","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2011-04","conditions":"Ejaculation","enrollment":24},{"nctId":"NCT02244255","phase":"PHASE4","title":"FLOMAX® Versus HYTRIN® in Patients With the Signs and Symptoms of Benign Prostatic Hyperplasia","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"1998-08","conditions":"Prostatic Hyperplasia","enrollment":1993},{"nctId":"NCT00237510","phase":"NA","title":"Pilot Study of Terazosin in Treatment of Antidepressant Induced Excessive Sweating","status":"COMPLETED","sponsor":"Thomas Jefferson University","startDate":"2005-05","conditions":"Antidepressant Induced Excessive Sweating","enrollment":15},{"nctId":"NCT00687388","phase":"PHASE4","title":"The Clinical Efficacy of Non-steroidal Anti-inflammation Drugs in Patients With Benign Prostatic Hyperplasia","status":"WITHDRAWN","sponsor":"Samsung Medical Center","startDate":"2008-05","conditions":"Benign Prostatic Hyperplasia","enrollment":""},{"nctId":"NCT00563485","phase":"NA","title":"Randomized Trial Comparing Terazosin 5 mg Daily and Doxazosin GITS 4 mg Daily for Trial Without Catheter in Acute Urinary Retention With Long Term Follow up","status":"TERMINATED","sponsor":"Hospital Authority, Hong Kong","startDate":"2005-10","conditions":"Prostatic Hyperplasia, Urinary Retention","enrollment":120},{"nctId":"NCT00700583","phase":"NA","title":"Alpha-blocker Plus Diuretic Combination Therapy as Second-line Treatment for Nocturia in Men","status":"COMPLETED","sponsor":"Seoul National University Hospital","startDate":"2008-05","conditions":"Nocturia","enrollment":72},{"nctId":"NCT00693199","phase":"NA","title":"Effect of Amlodipine Monotherapy or Combined With Terazosin on Lower Urinary Tract Symptoms and Hypertension","status":"COMPLETED","sponsor":"Anhui Medical University","startDate":"2006-07","conditions":"Lower Urinary Tract Symptoms, Hypertension","enrollment":360},{"nctId":"NCT00684489","phase":"NA","title":"Renin-Guided Therapeutics in the Management of Untreated, Uncontrolled, or Complicated Hypertension","status":"COMPLETED","sponsor":"Medical University of South Carolina","startDate":"2003-09","conditions":"Hypertension","enrollment":52}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":10,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Terazosin (Hytrin)","genericName":"Terazosin (Hytrin)","companyName":"Hospital Authority, Hong Kong","companyId":"hospital-authority-hong-kong","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Terazosin is an alpha-1 adrenergic receptor antagonist that relaxes smooth muscle in the prostate and bladder neck, improving urine flow and reducing symptoms of benign prostatic hyperplasia. Used for Benign prostatic hyperplasia, Hypertension.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}